1,047 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
JNJ Johnson & Johnson $139.96 $375.48B Uptrend
Article Searches
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs http://www.zacks.com/stock/news/415516/pharma-stock-roundup-fda-okays-line-extensions-of-lly-pfe-abbv-cancer-drugs?cid=CS-ZC-FT-415516 May 17, 2019 - FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
Did Geron's Big Announcement Just Go Unnoticed? https://www.fool.com/investing/2019/05/16/did-gerons-big-announcement-just-go-unnoticed.aspx?source=iedfolrf0000001 May 16, 2019 - Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod http://www.zacks.com/stock/news/408311/pharma-stock-roundup-mrk-lly-pfe-report-q1-earnings-sny-abbv-drugs-get-eu-nod?cid=CS-ZC-FT-408311 May 03, 2019 - Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/407492/why-johnson-johnson-jnj-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-407492 May 02, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
3 Warren Buffett Stocks Worth Buying Now https://www.fool.com/investing/2019/04/30/3-warren-buffett-stocks-worth-buying-now.aspx?source=iedfolrf0000001 Apr 30, 2019 - If you're looking to follow a master, Buffett is a good place to start. Though sometimes it pays to go back and double-check his moves.
Why This Could Be the Most Dangerous Time Ever to Invest in Healthcare Stocks https://www.fool.com/investing/2019/04/30/why-this-could-be-the-most-dangerous-time-ever-for.aspx?source=iedfolrf0000001 Apr 30, 2019 - There's a clear and present danger to many healthcare stocks that's more serious than anything ever before. Here's what you need to know.
Prescription for Success? https://www.fool.com/investing/2019/04/23/prescription-for-success.aspx?source=iedfolrf0000001 Apr 23, 2019 - Prescription drug sales, the future of Hulu, and more.
Here Are the Key Takeaways From J&J's Q1 Earnings Report http://www.zacks.com/stock/news/386860/here-are-the-key-takeaways-from-jjs-q1-earnings-report?cid=CS-ZC-FT-386860 Apr 18, 2019 - Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
JNJ Beats, Ups Sales Growth View: Healthcare ETFs in Focus http://www.zacks.com/stock/news/382902/jnj-beats-ups-sales-growth-view-healthcare-etfs-in-focus?cid=CS-ZC-FT-382902 Apr 17, 2019 - Johnson & Johnson continued its long streak of earnings beat and also outpaced revenue estimates. Though it raised the guidance for full-year sales growth, it tightened the earnings per share forecast.
Stock Market News For Apr 17, 2019 http://www.zacks.com/stock/news/382742/stock-market-news-for-apr-17-2019?cid=CS-ZC--382742 Apr 17, 2019 - Markets closed higher on Tuesday as investors welcomed a spate of healthy first quarter earnings results.

Pages: 123456...105

Page 1>